Thalassemia treatment depends on severity, ranging from no intervention at all for mild forms to lifelong blood transfusions, iron management, and potentially curative therapies for severe cases. Most people with thalassemia trait (carrying one affected gene) never need treatment. Those with moderate forms may need occasional transfusions and monitoring. People with thalassemia major, the most severe form, require regular transfusions every two to five weeks starting in early childhood, along with daily medication to remove excess iron from the body.
Regular Blood Transfusions
For transfusion-dependent thalassemia, the goal is to keep hemoglobin levels high enough that the body doesn’t try to compensate by expanding bone marrow production, which causes skeletal changes and organ enlargement over time. Transfusions are typically given every two to five weeks to maintain pre-transfusion hemoglobin above 9 to 10.5 g/dL. Patients with heart disease or those whose bone marrow remains overactive at that level may need a higher target of 11 to 12 g/dL, with post-transfusion levels kept below 14 to 15 g/dL.
Each transfusion visit generally takes a few hours. Over time, this becomes a rhythm of life. The transfusions themselves are straightforward, but they introduce a secondary problem: every unit of blood carries iron, and the human body has no efficient way to get rid of excess iron. After months and years of transfusions, iron accumulates in the heart, liver, and endocrine glands, causing damage if left unchecked.
Iron Chelation Therapy
Iron chelation, the process of binding excess iron so the body can excrete it, is essential for anyone on regular transfusions. Three FDA-approved chelation drugs exist, and the choice between them often comes down to how they’re taken, side effects, and what works best for the individual patient.
The oldest option is deferoxamine, which can’t be absorbed well by mouth and must be given through a slow infusion, either under the skin or into a vein. Patients typically use a portable pump to infuse the drug over 8 to 15 hours, five to seven nights per week. It’s effective but burdensome, especially for children and teenagers managing school and social life around nightly infusions.
Two oral alternatives have made daily chelation more manageable. Deferasirox is taken once a day, providing round-the-clock iron removal in a single dose. Deferiprone is taken three times a day and has shown particular strength in removing iron from the heart, making it valuable for patients with cardiac iron loading. Some patients use combinations of these drugs when a single agent isn’t controlling iron levels adequately.
Treatment for Milder Forms
Not everyone with thalassemia needs regular transfusions. People with non-transfusion-dependent thalassemia (sometimes called thalassemia intermedia) produce enough hemoglobin to survive without routine transfusions but often still have hemoglobin below normal levels. When hemoglobin drops below 10 g/dL, treatment to raise it can help prevent complications like bone changes, blood clots, and pulmonary hypertension.
Hydroxyurea, a medication that stimulates production of fetal hemoglobin (a form that works better in thalassemia), benefits some of these patients. It’s started at a low dose and gradually increased over several months. The response varies significantly based on genetics. Patients with certain genetic variants tend to see the most benefit, while others may not respond meaningfully. Some patients with milder disease still need occasional transfusions during illness, pregnancy, or surgery.
Reducing Iron Absorption Through Diet
For patients who aren’t transfusion-dependent, dietary iron absorption from the gut becomes a real concern because the body ramps up absorption when hemoglobin is low. A simple strategy: drinking black tea with meals can reduce non-heme iron absorption by 40 to 90%. Coffee has a similar effect, reducing absorption by about 39%. The tannins and polyphenols in these beverages bind iron in the gut before it enters the bloodstream. On the flip side, vitamin C increases iron absorption, so patients are generally advised to avoid taking vitamin C supplements or large amounts of citrus with meals.
Folic acid supplementation of 1 mg per day (or 5 mg per week) is recommended for most thalassemia patients, since the body uses folate rapidly when it’s constantly trying to produce new red blood cells.
Managing Long-Term Complications
Even with good chelation, iron accumulation over years can damage the endocrine system, bones, and other organs. Proactive screening catches these problems early.
Delayed puberty is common. Girls who show no pubertal development by age 12 and boys by age 14 need hormone evaluation. Boys should have testosterone levels checked annually starting around age 12. When levels are low, monthly hormone replacement helps drive normal development. Girls with absent or delayed periods may need estrogen replacement, typically started at a low dose and gradually increased before transitioning to an oral contraceptive.
Bone thinning is another frequent complication, driven by both iron toxicity and hormone deficiencies. Bone density screening starts at age 8 and continues annually. Calcium supplementation (up to 1,300 mg per day from age 9) and vitamin D (1,000 units per day for those with low levels) form the baseline prevention strategy. Patients who develop established osteoporosis may need additional medications to strengthen bone.
Newer Medications That Reduce Transfusion Needs
Luspatercept, a medication that helps red blood cells mature more effectively, was a significant addition for transfusion-dependent patients. In the BELIEVE clinical trial, 77% of patients achieved at least a 33% reduction in their transfusion burden during at least one 12-week period, with over 70% sustaining that response across multiple periods. That said, the effect is modest for many. When measured strictly during the trial’s primary window, only about one in five patients met the threshold for a meaningful response, and real-world results have been similar. For some patients, luspatercept meaningfully stretches the time between transfusions; for others, the benefit is minimal.
Stem Cell Transplant
A stem cell transplant (also called a bone marrow transplant) is currently the most established cure for thalassemia. It replaces the patient’s bone marrow with healthy donor marrow that can produce normal hemoglobin. The best outcomes occur in young children with a matched sibling donor. Thalassemia-free survival rates reach 88 to 93% in well-selected patients, meaning the vast majority never need transfusions again.
Transplant carries real risks, including graft failure (where the new marrow doesn’t take), graft-versus-host disease (where donor immune cells attack the patient’s body), and infection during the period when the immune system is suppressed. Older patients and those with liver enlargement or other organ damage from iron overload face higher risks, though newer conditioning regimens have improved outcomes in these groups. The decision to pursue transplant involves weighing the risks of the procedure against decades of transfusions and chelation.
Gene Therapy
Two gene therapies are now FDA-approved for transfusion-dependent beta thalassemia, offering a potential cure without needing a matched donor. The first, betibeglogene autotemcel (brand name Zynteglo), was approved in August 2022. It works by collecting a patient’s own stem cells, inserting a functional copy of the hemoglobin gene, and infusing the modified cells back after chemotherapy to clear the existing marrow.
The second, exagamglogene autotemcel (brand name Casgevy), was approved in January 2024 for patients 12 and older. It uses CRISPR gene-editing technology to reactivate fetal hemoglobin production, effectively bypassing the defective adult hemoglobin gene. Both therapies require a period of intensive chemotherapy before the modified cells are infused, followed by weeks of recovery in a specialized center. The process is demanding, but for patients who respond, it can eliminate or dramatically reduce the need for transfusions.
Access remains limited. These therapies are available only at specialized centers, carry price tags in the millions of dollars, and require patients to undergo chemotherapy conditioning, which has its own risks. Still, for younger patients without a matched donor who face decades of transfusion dependence, gene therapy represents a fundamentally different path.